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ABSTRACT
The breast cancer resistance protein (BCRP/ABCG2) is a maternallyfacing efflux transporter that regulates the placental disposition of
chemicals. Transcription factors and gene variants are important regulatory factors that influence transporter expression. In this study, we sought
to identify the genetic and transcriptional mechanisms underlying the
interindividual expression of BCRP mRNA and protein across 137
term placentas from uncomplicated pregnancies. Placental expression
of BCRP and regulatory transcription factor mRNAs was measured using
multiplex-branched DNA analysis. BCRP expression and ABCG2 genotypes were determined using Western blot and Fluidigm Biomark genetic
analysis, respectively. Placentas were obtained from a racially and
ethnically diverse population, including Caucasian (33%), African American (14%), Asian (14%), Hispanic (15%), and mixed (16%) backgrounds, as
well as unknown origins (7%). Between placentas, BCRP mRNA and

protein varied up to 47-fold and 14-fold, respectively. In particular, BCRP
mRNA correlated significantly with known transcription factor mRNAs,
including nuclear factor erythroid 2-related factor 2 and aryl hydrocarbon
receptor. Somewhat surprisingly, single-nucleotide polymorphisms
(SNPs) in the ABCG2 noncoding regions were not associated with
variation in placental BCRP mRNA or protein. Instead, the coding region
polymorphism (C421A/Q141K) corresponded with 40%–50% lower BCRP
protein in 421C/A and 421A/A placentas compared with wild types
(421C/C). Although BCRP protein and mRNA expression weakly correlated (r = 0.25, P = 0.040), this relationship was absent in individuals
expressing the C421A variant allele. Study results contribute to our
understanding of the interindividual regulation of BCRP expression in
term placentas and may help to identify infants at risk for increased fetal
exposure to chemicals due to low expression of this efflux protein.

Introduction

including carcinogens, chemotherapy drugs, endogenous compounds,
flavonoids, antibiotics, and antidiabetic drugs (Burger et al., 2004; Imai
et al., 2004; Merino et al., 2005; Gedeon et al., 2006; van Herwaarden et al.,
2006; Nakayama et al., 2011). BCRP is primarily localized to the apical
membrane of syncytiotrophoblasts as well as fetal capillary endothelial cells.
In syncytiotrophoblasts, BCRP actively transfers compounds out of the
placenta and back to the maternal circulation (Maliepaard et al., 2001; Jonker
et al., 2002; Szilagyi et al., 2017). Due to the critical role for BCRP in
protecting the fetus from exposure to xenobiotics, it is important to identify
regulators of constitutive BCRP expression in placenta, including transcription factors and single-nucleotide polymorphisms (SNPs).
BCRP/ABCG2 expression can be regulated by various transcription
factors, nuclear receptors, and steroid hormone receptors (Ee et al., 2004;
Krishnamurthy et al., 2004; Tompkins et al., 2010; Basseville et al., 2014)
(Fig. 1). The promoter region of the ABCG2 gene is well characterized and
contains response elements for transcriptional regulators, including the aryl

In the placenta, the breast cancer resistance protein (BCRP/ABCG2) efflux
transporter plays an important role in limiting fetal exposure to chemicals,
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ABBREVIATIONS: AHR, aryl hydrocarbon receptor; BCRP, breast cancer resistance protein; ER, estrogen receptor; HIF1a, hypoxia-inducible
factor 1a; NRF2, nuclear factor erythroid 2-related factor 2; PBS/T, phosphate-buffered saline with 0.5% Tween 20; PPARg, peroxisome
proliferator-activated receptor g; PR, progesterone receptor; SNP, single-nucleotide polymorphism; 59UTR, 59 untranslated region.
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Fig. 1. Map of transcription factor and nuclear receptor response elements in the promoter region of the ABCG2 gene. Location of response elements numbered with respect
to the transcriptional start site (TSS, +1) and the first nucleotide of the gene (+1; AC084732).

hydrocarbon receptor (AHR) (Tompkins et al., 2010), estrogen receptor a
(ERa/ESR1) and b (ERb/ESR2) (Ee et al., 2004), hypoxia-inducible factor a
(HIF1a) (Krishnamurthy et al., 2004), nuclear factor erythroid 2-related factor
2 (NRF2) (Singh et al., 2010), peroxisome proliferator-activated receptor g
(PPARg) (Szatmari et al., 2006), progesterone receptor (PR) (Wang et al.,
2008), SP1 transcription factor (SP1) (Bailey-Dell et al., 2001), and SP3
transcription factor (SP3) (Yang et al., 2013). Despite the identification of
functional regulatory elements, the relationship between these transcription
factors and BCRP in term human placentas has largely been unexplored.
A number of SNPs have been identified in the ABCG2 gene
(chromosome 4q22, ABCG2; Fig. 2) (Zamber et al., 2003; de Jong
et al., 2004; Kobayashi et al., 2005; Poonkuzhali et al., 2008). The most
well-characterized genetic variants are localized to the coding region of
the ABCG2 gene and result in amino acid changes in the subsequent
BCRP protein (i.e., G34A→V12M and C421A→Q141K) (Zamber
et al., 2003; de Jong et al., 2004; Kobayashi et al., 2005). The C421A
variant is often observed in Asian (allele frequency: 0.35) and Caucasian
(allele frequency: 0.10) populations (Zamber et al., 2003; Kobayashi
et al., 2005). Importantly, the C421A variant has been associated with
the altered pharmacokinetics and pharmacodynamics of drugs in patients
that express one or two variant alleles, most likely due to reduced BCRP
function in the intestine, liver, and/or kidneys. For example, lung cancer

patients with one variant allele (421C/A) have a 3.7-fold greater risk of
developing severe diarrhea, a toxic side effect of the BCRP substrate and
chemotherapeutic drug gefitinib (Cusatis et al., 2006). Furthermore,
healthy volunteers that were homozygous for the variant (421A/A)
exhibited significantly greater area-under-the-curve values and maximal
concentrations for the hypolipidemic drug rosuvastatin following a
20 mg oral dose as compared with those with no (421C/C) or one
(421C/A) mutant allele (Keskitalo et al., 2009). Due to these data and
additional reports, the International Transporter Consortium recommended that the C421A polymorphism be considered in clinical drug
development (Giacomini et al., 2013).
Genetic variants that occur in the noncoding region of the ABCG2 gene
have begun to emerge as regulators of BCRP expression and are being
evaluated for their clinical relevance. SNPs in the 59 untranslated region and
intronic regions of the ABCG2 gene have been associated with variation in
BCRP mRNA expression in intestinal, liver, and lymphoblast samples
(Poonkuzhali et al., 2008). Importantly, the effect of noncoding variants on
BCRP expression and function in the placenta warrants investigation.
Therefore, the purpose of this study was to identify factors, including infant
sex, ethnicity/race, transcription factor relationships, and genetic variants,
that contribute to the interindividual expression of BCRP mRNA and
protein expression in term placentas from uncomplicated pregnancies.

Fig. 2. Map of SNPs in the noncoding and coding regions of the ABCG2 gene. Noncoding SNPs are numbered according to the first nucleotide of the gene (+1; AC084732),
and coding SNPs are numbered according to the translational start site (+1) and exclude nucleotides in noncoding regions. When applicable, ABCG2 SNPs that result in
amino acid changes in the BCRP protein are denoted with an arrow (→).

Interindividual BCRP Expression in Placenta
TABLE 1
Placenta donor demographic information (N = 137)
Parameter

Clinical Characteristics of Pregnancies and Placentas Obtained

Gestational age (wk)
Maternal age (yr)
Placental weight (g)b
Birth weight (g)
Infant sexc

38.8 6 1.1a
31.2 6 4.9a
660.0 6 154.5a
3355.3 6 426.3a
Female = 65, Male = 69

Mean 6 S.D.
Wet, untrimmed weight.
Sex was unknown for three infants.

a
b
c

Materials and Methods
Placenta Donor Selection. One hundred and thirty-seven placentas were
obtained by written informed consent from women with uncomplicated
pregnancies across two institutions (Robert Wood Johnson University Hospital,
New Brunswick, NJ, N = 108; University of California, San Francisco, CA, N = 29).
Participant inclusion criteria for this study were healthy women, ages 18–40,
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term gestation, scheduled Cesarean sections, and vaginal deliveries (University of
California only). Exclusion criteria were pregnancy-induced medical conditions
(i.e., pregnancy-induced hypertension, pre-eclampsia, gestational diabetes),
chronic medical disorders (i.e., hypertension, diabetes, autoimmune diseases),
maternal infection, clinical chorioamnionitis, medication use (except for prenatal
vitamins), maternal alcohol or drug use, and known fetal chromosomal
abnormalities. Placenta donor demographic information is listed in Table 1.
Ethnicity and race were self-reported. Where possible, infant ethnicity and race
were obtained from both maternal and paternal reporting. In the absence of
paternal information, the ethnicity and race of the mother were used. This study
was approved by the Institutional Review Boards of Robert Wood Johnson
Medical School (Protocol 0220100258), Rutgers University (Protocols E12-024
and #E14-325), and the University of California (Protocol 10-00505).
Sample Collection. Placentas were collected within 10 minutes of delivery for
processing within 1 hour. Visible abnormalities and the location of the umbilical
cord were assessed, and only normal placentas with central or eccentric cord
insertions were used. A small piece of umbilical cord close to the placenta was
placed in a PAXgene Tissue Container (Qiagen, Germantown, MD) in the
PAXgene Tissue Fix for 4 hours at 4C, moved to PAXgene Tissue Stabilizer, and
stored at 280C for ABCG2 SNP genotyping. To sample placental tissue, the

Fig. 3. Evaluation of placental BCRP expression by infant ethnicity/race. (A) mRNA expression of BCRP was assessed in 137 term placentas using a multiplex-branched
DNA signal amplification assay. BCRP mRNA values were normalized to the geometric mean of two references genes, glyceraldehyde-3-phosphate dehydrogenase and
ribosomal protein L13A. (B) Protein expression of BCRP was assessed in 70 term placentas by Western blot analysis. b-Actin was used as a loading control. Data are
presented as box and whisker plots using the Tukey method with medians marked by a horizontal line. The box contains 50% of the data, whereas the length of the whiskers
from the edge of the box is equal to the lesser of either 1.5 times the interquartile range or the distance to the minimum/maximum value. Dots represent individual expression
values that fall more than 1.5 times the interquartile range beyond the 25th and 75th quartiles. The bars represent individual placental BCRP expression.
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Fig. 4. Correlation between BCRP mRNA and protein expression. mRNA
expression of BCRP was assessed in 70 term placentas using a multiplex-branched
DNA signal amplification assay. BCRP mRNA values were normalized to the
geometric mean of two references genes, glyceraldehyde-3-phosphate dehydrogenase and ribosomal protein L13A. Protein expression of BCRP was assessed in the
same term placentas by Western blot analysis. b-Actin was used as a loading
control. Correlation between BCRP mRNA and protein expression was determined
using the Pearson linear method (r = 0.25, P = 0.040).

overlying membranes, maternal decidua, and chorionic plate were removed.
From the maternal side of the placenta, two pieces of chorionic tissue were
collected along the long axis approximately 1 cm distal to the cord insertion site,
as described (Memon et al., 2014). It was previously shown that BCRP expression
does not change across the placental disc (Memon et al., 2014). The dimensions
of each sample were approximately 2  1  0.5 cm. After rinsing three times
with sterile phosphate-buffered saline to remove maternal blood, each sample
was further dissected into two subsegments of equal size for RNA and protein
analysis. Tissues were placed in PAXgene Tissue Containers and processed, as
described above. Samples were stored at 280C until further analysis. For
assessment of protein expression, samples were snap frozen in liquid nitrogen
and stored at 280C.
Single-Nucleotide Polymorphism Genotyping. Umbilical cord samples
were homogenized, and total DNA was isolated with the PAXgene Tissue
DNA Kit (Qiagen). A DropSense96 UV/Vis droplet reader was used to quantify
total DNA and confirm the integrity of the DNA (Trinean, Gentbrugge, Belgium).
The Fluidigm BioMark Genetic Analysis system was used to genotype 20 ABCG2
gene SNPs (Fig. 2) in the Bionomics Research and Technology Center at Rutgers
University. Primer sequences used for ABCG2 SNP analysis are provided in
Supplemental Tables 1–4.
RNA Isolation and Multiplex-Branched DNA Assay. PAXgene-stabilized
placental tissues were homogenized using a TissueLyser (2 minutes, 50 Hz;
Qiagen) in TR1 buffer provided in the PAXgene Tissue RNA Kit (Qiagen) plus
1% b-mercaptoethanol. Total RNA was isolated with the PAXgene Tissue RNA
Kit (Qiagen), according to the manufacturer’s instruction. Concentration of total
RNA was determined using a Nanodrop spectrophotometer (Thermo Fisher
Scientific, Waltham, MA), and integrity was confirmed using a 2100 Bioanalyzer
instrument (Agilent, Santa Clara, CA). A multiplex-branched DNA signal
amplification assay (QuantiGene Assay; Affymetrix, Santa Clara, CA) and a
Bio-Plex MAGPIX multiplex reader (Bio-Rad, Hercules, CA) were used to
quantify mRNA expression of BCRP, AHR, ERa, ERb, HIF1a, NRF2, PPARg,
PR, SP1, and SP3. The number of target RNA molecules detected in each sample
was proportional to the assay readout, median fluorescence intensity. Data were
normalized to the geometric mean of the median fluorescence intensity for two
reference genes that were previously determined to have low correlation with
placental BCRP mRNA expression, glyceraldehyde-3-phosphate dehydrogenase
and ribosomal protein L13A (Memon et al., 2014). Probe information is provided
in Supplemental Table 5.
Western Blot. Samples were processed for Western blot analysis, as
previously described (Memon et al., 2014). Briefly, frozen placenta samples
were homogenized in a sucrose (250 mM)–Tris base (10 mM) buffer (pH 7.5)
with protease inhibitors (1%; Sigma-Aldrich, St. Louis, MO). Following
centrifugation (100,000g) for 1 hour at 4C, pellets containing crude membrane

Fig. 5. Evaluation of placental BCRP expression by infant sex. (A) mRNA expression
of BCRP was assessed in 137 term placentas using a multiplex-branched DNA signal
amplification assay. BCRP mRNA values were normalized to the geometric mean of
two references genes, glyceraldehyde-3-phosphate dehydrogenase and ribosomal
protein L13A. (B) Protein expression of BCRP was assessed in 70 term placentas by
Western blot analysis. b-Actin was used as a loading control. Data are presented as box
and whisker plots using the Tukey method with medians marked by a horizontal line.
The box contains 50% of the data, whereas the length of the whiskers from the edge of
the box is equal to the lesser of either 1.5 times the interquartile range or the distance to
the minimum /maximum value. Dots represent individual expression values that fall
more than 1.5 times the interquartile range beyond the 25th and 75th quartiles.

fractions were resuspended in sucrose–Tris base buffer with protease inhibitors.
Protein concentrations were measured by a bicinchoninic acid assay (Pierce
Biotechnology, Rockford, IL). Western blot analysis was performed by adding
10 mg total protein to polyacrylamide 4%–12% Bis–Tris gels (Life Technologies,
Carlsbad, CA) that were resolved by electrophoresis. Gels were carefully
trimmed, as previously described (Kiyatkin and Aksamitiene, 2009), and the
same size proteins were transferred to polyvinylidene fluoride membranes in
overnight transfer apparatuses onto the same membrane (Bio-Rad Criterion
Blotter). This approach allowed protein samples from all placentas to be directly
compared on the same transblotted membrane. This procedure was performed
twice for each of the two sampling sites within the placentas. Membranes
including all the samples were blocked in 5% nonfat dairy milk in phosphatebuffered saline with 0.5% Tween 20 (PBS/T) for 1 hour. Primary antibodies
(BCRP, BXP-53, 1:5000, Enzo Life Scientific, Farmingdale, NY; b-actin,
Ab8227, 1:2000, Abcam, Cambridge, MA) were diluted in 2% nonfat milk in
0.5% PBS/ T and incubated with the membranes overnight at 4C. After washing
with PBS/ T, horseradish peroxidase–conjugated secondary antibodies were
added to the blots for 1 hour. Supersignal West Dura Extended Duration
Substrate (Pierce Biotechnology) was used for chemiluminescent detection of
proteins using a Fluorchem Imager (ProteinSimple, Sanata Clara, CA). Band
densities were semiquantitated using the AlphaView Software (ProteinSimple).
BCRP band density for each sample was normalized to its respective b-actin
(loading control) band density.
Statistical Analysis. Separate linear regression models were used to compare
both relative BCRP mRNA expression and relative BCRP protein expression to
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TABLE 2
Univariate associations between individual transcription factors and BCRP mRNA expression
Parameter Estimate

S.E. of Parameter Estimate

t-Statistic

Unadjusted P Value

Adjusted P Value

0.85
0.29
0.40
1.14
0.64
36.57
10.76
10.86
1.20

0.11
0.04
0.06
0.24
0.23
19.86
8.10
8.19
0.94

7.97
7.05
6.16
4.67
2.76
1.84
1.33
1.33
1.27

6.1e213
8.6e211
7.9e209
7.2e206
6.7e203
6.8e202
1.9e201
1.9e201
2.1e201

5.5e212
7.7e210
7.1e208
6.5e205
6.0e202
6.1e201
1.0e+00
1.0e+00
1.0e+00

NRF2
AHR
SP3
SP1
HIF1a
ESR2
ESR1
PR
PPARg

race and ethnicity, infant sex, placenta weight, infant weight, transcription factor
expression (BCRP mRNA expression only), and SNPs (using an additive model).
For relative BCRP mRNA expression, these linear regression models also
included a fixed effect of collection site to account for overall differences in
expression between collection sites. Adjusted relative BCRP mRNA expression
values were used for figures and were calculated from the linear regression model
that included collection site. Because BCRP protein expression values were
calculated only at one site, no adjustment was needed. Effects are reported as the
parameter estimate (b) from the regression model, i.e., the relative change in
BCRP mRNA or protein expression associated with a 1 U change in the predictor
variable. The comparison between protein expression and BCRP mRNA
expression used a Pearson correlation coefficient and only included samples
from one site. To compare transcription factor expression to one another, a
pairwise Pearson correlation analysis was employed. All statistical analyses were
carried out using the R statistical package (Version 3.4.1). Statistical significance
was set to P , 0.05. P values were adjusted using a Bonferroni correction to
account for multiple comparisons.

Results
Interindividual Expression of BCRP in Term Human Placentas.
From the lowest- to the highest-expressing placenta, BCRP mRNA and
protein expression varied up to 47-fold (N = 137) and 14-fold (N = 70),
respectively (Fig. 3). There was no association between infant

ethnicity/race and either BCRP mRNA or protein (Fig. 3). Interestingly,
BCRP protein expression demonstrated a weak, but significant,
correlation with BCRP mRNA expression (r = 0.25, P = 0.040) (Fig. 4).
There were no significant differences in BCRP mRNA or protein
between term placentas from female and male infants (Fig. 5).
Additionally, neither infant weight nor placental weight correlated with
BCRP mRNA expression (Supplemental Fig. 1).
Correlation of Transcription Factor Expression with BCRP
Expression. The mRNAs of nine transcription factors known to regulate
BCRP expression (AHR, ERa, ERb, HIF1a, NRF2, PPARg, PR, SP1,
SP3) were quantified in human term placentas (N = 137). Univariate
regression analysis revealed that BCRP mRNA correlated most closely
to NRF2 (b = 0.85; P , 0.0001) and AHR (b = 0.29; P , 0.0001)
mRNAs (Table 2). Furthermore, the mRNA expression of multiple
transcription factors correlated well with each other, notably NRF2 with
SP1 (r = 0.74; P , 0.0001) and AHR with SP3 (r = 0.73; P , 0.0001)
(Supplemental Fig. 2; Supplemental Table 6).
Assessment of ABCG2 Genetic Variants as Contributors to
Variation in Placental BCRP Expression. Twenty SNPs in the
noncoding and coding regions of the ABCG2 gene were assessed in
137 human term placentas (Fig. 2). Although allele frequencies varied by
SNP, noncoding region SNPs occurred more frequently than those in the

TABLE 3
Allele frequencies of SNPs separated by ethnicity/race
Allele Frequencyb
dbSNPd

rs2127862
rs2127861
rs13135956
rs141093520
rs55930652
rs2725226
rs3114020
rs2622604
rs3109823
rs3114018
rs2725250
rs2622620
rs2046134
rs2231137
rs186749266
rs2231139
rs72552713
rs2231142
rs2725267
rs2231164
a

Gene Location Gene Positiona

59UTR
59UTR
59UTR
59UTR
59UTR
59UTR
59UTR
Intron 1
Intron1
Intron 1
Intron 1
Intron 1
Intron 1
Exon 2
Intron 2
Exon 4
Exon 4
Exon 5
Intron 14
Intron 14

C46847T
G46932C
G59582A
A61562C
C61785T
C72144T
T73809C
C78551T
A92873G
A92894C
T93490C
C93624A
G94112A
G34Ac
A96567G
C369Tc
C376Tc
C421Ac
T141300C
A141618G

African American

Asian

0.47
0.11
0.53
0.026
0.11
0.19
0.32
0.11
0.61
0.24
0.34
0.24
0.42
0
0.056
0.11
0
0.026
0.64
0.63

0.21
0
0.13
0.16
0.13
0.53
0.53
0.16
0.26
0.55
0.26
0.53
0.083
0
0.18
0
0
0.32
0.11
0.37

Caucasian Hispanic Mixed Unknown Overall

0.45
0.13
0.20
0.078
0.17
0.41
0.41
0.13
0.22
0.47
0.35
0.38
0.033
0.011
0.10
0
0.023
0.011
0.11
0.13

0.28
0.1
0.15
0.075
0.13
0.6
0.63
0.10
0.15
0.70
0.28
0.58
0.05
0.13
0.2
0.025
0
0.2
0.43
0.6

0.3
0.07
0.21
0.071
0.18
0.5
0.5
0.14
0.36
0.57
0.33
0.45
0.13
0.09
0.14
0
0.024
0.048
0.43
0.45

0.28
0.17
0.06
0
0.22
0.61
0.61
0.22
0.22
0.78
0.17
0.78
0
0
0.056
0
0
0.28
0
0.22

0.35
0.097
0.22
0.074
0.15
0.45
0.47
0.13
0.29
0.52
0.31
0.44
0.11
0.036
0.13
0.019
0.011
0.11
0.28
0.36

AC084732 (first nucleotide of gene = 1).
Allele frequency was calculated by dividing the number of variant alleles by the total number of alleles (number of individuals  2) in a
population.
c
Starting at translational start site (+1) and excluding nucleotides in noncoding regions.
d
dbSNP: NCBI SNP database number.
b
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TABLE 4
Univariate associations between SNPs and BCRP mRNA expression

SNPa,b

Regression Parameter Estimate for
Additive Effect on BCRP mRNA
Expression

S.E. of Parameter Estimate for
Additive Effect on BCRP mRNA
Expression

t-Statistic for SNP Effect on
BCRP mRNA Expression

C46847T
G46932C
G59582A
A61562C
C61785T
C72144T
T73809C
C78551T
A92873G
A92894C
T93490C
C93624A
G94112A
A96567G
C421Ac
T141300C
A141618G

20.0082
0.0014
0.0016
20.0294
0.0019
0.0040
0.0060
0.0066
0.0031
20.0062
0.0035
0.0091
20.0147
20.0072
0.0029
20.0013
20.0009

0.0082
0.0129
0.0094
0.0155
0.0104
0.0074
0.0074
0.0109
0.0079
0.0074
0.0081
0.0075
0.0109
0.0127
0.0109
0.0085
0.0074

21.00
0.11
0.17
21.90
0.18
0.55
0.82
0.61
0.39
20.84
0.43
1.22
21.36
20.57
0.26
20.15
20.12

P Value for SNP Effect on Bonferroni-Adjusted P Value for SNP
BCRP mRNA Expression
Effect on BCRP mRNA Expression

0.318
0.912
0.864
0.060
0.857
0.586
0.415
0.543
0.695
0.401
0.665
0.225
0.177
0.570
0.794
0.882
0.903

1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000

a

AC084732 (first nucleotide of gene = 1).
SNPS G34A, C369T, and C376T were removed from analysis due to small sample size.
Starting at translational start site (+1) and excluding nucleotides in the noncoding region.

b
c

exonic regions (Table 3). Most of the genetic variants located in the coding
region of the ABCG2 gene occurred at low frequencies (G41A, C369T,
C376T; Table 3), such that statistical analysis in relation to BCRP mRNA or
protein expression could not be performed.
Overall, individuals heterozygous for the A61562C variant in the 59
untranslated region (59UTR) tended to exhibit reduced BCRP mRNA
expression (Table 4), although this was not statistically significant.
Interestingly, there were no individuals homozygous for the A61562C
SNP. No other associations between SNPs and BCRP mRNA expression were observed.
In a representative population of samples from a single collection site
(N = 70), analysis of BCRP protein expression revealed a negative trend
for two SNPs in noncoding regions, C72144T (59UTR) and C93624A
(intron 1) (Table 5). The C421A SNP located in exon 5 occurred at 11%
of the overall sample population but was most frequent in Asian and
Hispanic populations occurring at 32% and 20%, respectively. Although

the C421A variant was not associated with altered BCRP mRNA
expression (Fig. 6; Table 4), at the protein level, the C421A genotype
had a significant effect on BCRP protein expression. Importantly,
individuals that were homozygous for the variant (421A/A) had 50%
lower BCRP expression in placentas as compared with the wild-type
genotype (421C/C) (Fig. 6; Table 5). Of note, heterozygous individuals
(421C/A) similarly exhibited 40% lower BCRP protein expression.
Finally, BCRP mRNA and protein expression correlated in 421C/C
individuals (r = 0.29, P = 0.032). This relationship was not observed in
placentas expressing one or two variant alleles (421C/A, r = 0.13 and
P = 0.75; 421A/A, r = 0.16 and P = 0.84) (Fig. 6C).
Discussion
This study characterized interindividual differences in the mRNA and
protein expression of the BCRP transporter in term placentas from

TABLE 5
Univariate associations between SNPs and BCRP protein expression
SNPa,b

Regression Parameter Estimate for
Additive Effect on BCRP Protein
Expression

S.E. of Parameter Estimate for
Additive Effect on BCRP Protein
Expression

C46847T
G46932C
G59582A
A61562C
C61785T
C72144T
T73809C
C78551T
A92873G
A92894C
T93490C
C93624A
G94112A
A96567G
C421Ac
T141300C
A141618G

0.0247
20.0023
0.0213
0.0097
0.0120
20.0279
20.0210
0.0227
0.0142
0.0207
0.0102
20.0294
0.0104
0.0008
20.0666
0.0097
20.0227

0.0169
0.0256
0.0178
0.0326
0.0215
0.0148
0.0147
0.0227
0.0158
0.0151
0.0180
0.0154
0.225
0.0274
0.0195
0.0184
0.0147

a

AC084732 (first nucleotide of gene = 1).
SNPS G34A, C369T, and C376T were removed from analysis due to small sample size.
Starting at translational start site (+1) and excluding nucleotides in the noncoding region.

b
c

t-Statistic for SNP Effect on P Value for SNP Effect on Bonferroni-Adjusted P Value for SNP
BCRP Protein Expression
BCRP Protein Expression
Effect on BCRP Protein Expression

1.46
20.09
1.20
0.30
0.56
21.88
21.42
1.220
0.90
0.137
0.57
21.91
0.46
0.03
23.42
0.53
21.54

0.149
0.928
0.235
0.767
0.578
0.065
0.159
0.227
0.373
0.175
0.574
0.060
0.646
0.976
0.001
0.598
0.127

1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
1.000
0.018
1.000
1.000
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Fig. 6. Association of the C421A coding region SNP with placental BCRP expression. (A) mRNA expression of BCRP was assessed in 137 term placentas using a
multiplex-branched DNA signal amplification assay. BCRP mRNA values were normalized to the geometric mean of two references genes, glyceraldehyde-3-phosphate
dehydrogenase and ribosomal protein L13A. (B) Protein expression of BCRP was assessed in 70 term placentas by Western blot analysis. b-Actin was used as a loading
control. Data are presented as a representative Western blot and according to C421A genotype using box and whisker plots using the Tukey method with medians marked by
a horizontal line. The box contains 50% of the data, whereas the length of the whiskers from the edge of the box is equal to the lesser of either 1.5 times the interquartile range
or the distance to the minimum /maximum value. Dots represent individual expression values that fall more than 1.5 times the interquartile range beyond the 25th and 75th
quartiles. Asterisks (*) represent statistically significant differences (P , 0.05) compared with wild-type control (C/C) using a Kruskal–Wallis nonparametric test with a
Dunn’s multiple testing correction. (C) Association of BCRP mRNA and protein expression by genotype was assessed by Pearson correlation.

ethnically and racially diverse pregnant women with uncomplicated
pregnancies. There were no differences in BCRP mRNA or protein
expression according to infant sex or ethnicity/race. Additionally,
expression of BCRP mRNA weakly correlated with protein levels in a
representative population of placentas (N = 70). BCRP mRNA
expression correlated to the greatest extent with the mRNA expression
of two transcription factors, NRF2 and AHR. Overall, SNPs in the
noncoding regions of the ABCG2 gene were not associated with changes
in BCRP mRNA or protein expression. However, there was up to a 50%
reduction in BCRP protein in term placentas expressing a common SNP
located in the fifth exon (C421A). Taken together, these data suggest that
the C421A genetic variant has the greatest influence on placental BCRP
protein expression.
We observed no significant differences in BCRP mRNA or protein
expression based on infant sexes (Fig. 5). In contrast, other laboratories
have demonstrated that BCRP is more highly expressed in the intestines
and livers of adult females compared with males (Zamber et al., 2003;
Prasad et al., 2013). Differences may be due to variation in the
expression of BCRP regulatory factors across tissues or during different
developmental ages.
Of the transcription factors assessed, AHR and NRF2 mRNAs exhibited
the greatest associations with BCRP mRNA (Table 2). This is similar to the
relationships reported between mouse placental Ahr and Bcrp mRNAs
(r = 0.78, P , 0.01) compared with other screened transcription factor
mRNAs (Hif1a, Era, Erb, Pr) (Wang et al., 2006). However, in human
placenta cell culture, two studies have reported conflicting findings regarding
the regulation of BCRP by the AHR signaling pathway. The prototypical
AHR activator 3-methylcholanthrene (24 hour) significantly enhanced the
mRNA expression of AHR target gene CYP1A1 without changing BCRP

levels in human term placental trophoblasts (Stejskalova et al., 2011). By
comparison, the AHR antagonist CH223191 prevented a maximal 10-fold
upregulation of BCRP mRNA by opioid receptor agonists methadone,
buprenophrine, and norbuprenorphine in placenta choriocarcinoma
cells (BeWo and JEG3) and primary human villous trophoblasts
(Neradugomma et al., 2017). Based on these findings, additional
mechanistic investigations are needed to demonstrate a causal relationship between AHR and BCRP expression in term placentas.
The relationship between the NRF2 transcription factor and BCRP
has not been explored in the placenta. Typically, NRF2 localizes to
antioxidant response elements in the promoter region of genes involved
in detoxification pathways, including NAD(P)H quinone oxidoreductase 1. In rat brain capillaries, Bcrp protein and function were
significantly increased following exposure to the prototypical NRF2
activator sulforaphane (Wang et al., 2014). Moreover, Singh et al. (2010)
reported NRF2 directly interacts with an antioxidant response element in
the promoter of the ABCG2 gene and observed a downregulation of
BCRP mRNA in human lung cancer cells in response to the genetic
knockdown of NRF2 with a targeted short hairpin RNA. In human
choriocarcinoma JEG3 cells, NRF2 is expressed and, upon treatment
with acetaminophen (48 hour), resulted in an approximate 40% increase
in NAD(P)H quinone oxidoreductase 1 gene expression; however,
BCRP mRNA expression was not assessed (Blazquez et al., 2014). A
detailed investigation of the relationship between human placental
NRF2 and BCRP may provide mechanistic information regarding the
fetoprotective pathways of the placenta during healthy conditions and
in the presence of oxidative and cellular stress.
Although BCRP mRNA expression correlated with AHR and NRF2
mRNA expression in term placentas, it is unclear whether this relationship
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is established early in pregnancy. There are conflicting data regarding the
expression of BCRP across gestation as three independent research groups
reported a reduction (mRNA and protein) (Meyer zu Schwabedissen et al.,
2006), no change (protein and mRNA) (Mathias et al., 2005), and an
increase (only protein) (Yeboah et al., 2006) in BCRP expression with
advancing gestational age. Future studies should assess the mRNA and
protein expression of BCRP, AHR, and NRF2 of first-, second-, and thirdtrimester placentas to better characterize the relationship between BCRP
and the two transcription factors during placental development.
In a prior study, noncoding SNPs in the ABCG2 gene correlated with high
(A61562C, G94112A) or low (G46932C, C61785T, C78551T) BCRP
mRNA expression in liver, intestine, and lymphoblasts (Poonkuzhali et al.,
2008). The proposed underlying mechanisms for differential BCRP mRNA
expression included changes in the binding of specific transcription factors
(promoter region, 59UTR) and/or disruption of gene splicing (introns)
(Boccia et al., 1996; Wang and Sadee, 2016). Since the initial investigation
by Poonkuzhali et al. (2008), three of the noncoding ABCG2 SNPs have
been linked to altered pharmacodynamics of BCRP substrates. In the first
intron, the C78551T and A92873G variants have been associated with the
development of severe myelosuppression as a side effect of the anticancer
drug irinotecan (Cha et al., 2009). Also, in the first intronic region, the
A92894C variant has been associated with altered pharmacokinetic
parameters in patients treated with the epilepsy drug, lamotrigine;
significantly higher blood concentrations were observed in subjects
heterozygous or homozygous for the A92894C variant (Zhou et al.,
2015).
This is the first report investigating the association of placental BCRP
expression with genetic variants in the noncoding region of the ABCG2
gene. Only one SNP in the 59UTR (A61562C) tended to be associated
with lower BCRP expression. Despite prior associations between noncoding variants and BCRP expression in liver, intestine, and lymphoblasts (Poonkuzhali et al., 2008), there may be differences in gene
regulation across tissues. Tissue-specific effects have been reported for
intronic SNPs occurring in the CYP3A4 gene. Human livers with the
intronic variant CYP3A4*22 exhibited lower CYP3A4 mRNA expression, which was not observed in the intestines (Wang and Sadee, 2016).
Segregation of mRNA expression data by ethnicity and genotype may
uncover additional associations between ABCG2 SNP and BCRP mRNA
expression; however, our sample size limited the ability to conduct this
analysis. We also examined SNPs occurring in the coding region of the
ABCG2 gene. Individuals that were homozygous for the coding region
variant (C421A) had 50% less BCRP protein than the wild-type controls,
with no differences in BCRP mRNA. This is in agreement with a study
performed in 2005, which examined BCRP expression in 100 placentas
from healthy Japanese women (Kobayashi et al., 2005).
We observed a weak but statistically significant correlation between
BCRP mRNA and protein (Fig. 4), suggesting that, in some cases,
mRNA levels may be a surrogate measure for understanding BCRP
protein expression in term human placentas. However, the correlation
coefficient (r = 0.25) revealed that variation in BCRP protein is not
solely dependent on mRNA expression and that other regulatory
mechanisms, including microRNAs (Saito et al., 2013) and posttranscriptional modifications (Imai et al., 2005), may be important.
Two other studies found no correlation between the BCRP gene and
protein expression in other normal human tissues, including intestine
(N = 42) and liver (N = 65) (Zamber et al., 2003; Prasad et al., 2013),
further emphasizing the importance of understanding tissue-specific
differences in the regulation of BCRP expression.
In summary, these data demonstrate the interindividual expression of
placental BCRP in term placentas from uncomplicated pregnancies and
reveal associations of BCRP with genetic variants as well as transcription
factors. These findings add to our understanding of the regulation of

placental BCRP expression in normal term pregnancies and provide a
foundation for identifying individuals that may be at risk for reduced
BCRP expression and function.
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